NCT03241888View on ClinicalTrials.gov

Megestrol Acetate Plus LNG-IUS in Young Women With Endometrial Atypical Hyperplasia

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

July 4, 2017

Primary Completion Date

June 18, 2020

Study Completion Date

June 18, 2020

Conditions
Atypical Endometrial Hyperplasia
Interventions
DRUG

Megestrol Acetate

At a dosage of 160 mg/day

DEVICE

Levonorgestrel-releasing Intrauterine System(LNG-IUS)

Active ingredient: levonorgestrel 52mg. It is a hormone-releasing T-shaped intrauterine system.

Trial Locations (1)

200011

Obstetrics and Gynecology Hospital, Fudan University, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER

NCT03241888 - Megestrol Acetate Plus LNG-IUS in Young Women With Endometrial Atypical Hyperplasia | Biotech Hunter | Biotech Hunter